ZUO LI YAO YE(SZ:300181)2024-08-07 09:37Group 1: Sales Performance - The sales of Wuling Capsules cover over 13,000 hospitals, with more than 50% being primary hospitals and community health centers, but revenue is primarily from secondary and tertiary hospitals [3] - In the first half of the year, the sales from the OTC and online channels accounted for just over 10%, with a goal to increase this to at least 20% [4] - Lingze Tablets have shown significant sales growth, with revenue increasing from over 10 million in 2019 to over 200 million last year, and a target of 500 million for the first step [4][5] Group 2: Market Expansion - Wuling Capsules have not yet been included in centralized procurement in provinces such as Shanghai, Zhejiang, and Sichuan [3] - The company sees potential for expanding its core products in over one million medical institutions across various levels [5] - The company aims to enhance its focus on grassroots medical institutions to increase sales proportion [3] Group 3: Research and Development - The company is conducting research on MCI (Mild Cognitive Impairment) and its related treatments, with a focus on community health centers for early screening [3] - Ongoing development of improved formulations of Wuling Capsules is in progress, particularly for AD (Alzheimer's Disease) efficacy studies [3] Group 4: Target Demographics - The consumer base for Wuling Capsules spans all age groups, from students to the elderly, reflecting a broad market for addressing insomnia, anxiety, and depression [4] - Regions with higher economic development, such as Zhejiang and Guangdong, show a higher sales proportion due to greater awareness of mental health issues [4]